Biotechnology & Medical Research

ZS Pharma announces FDA acceptance of ZS-9 new drug application

ZS Pharma Inc:Says its New Drug Application (NDA) for ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalemia, has been accepted for filing by the United States Food and Drug Administration (FDA).PDUFA goal date for a decision by the FDA is may 26, 2016.

4:01pm EDT

Affymetrix Inc reaffirms FY 2015 revenue outlook; raises FY 2015 EBITDA outlook

Affymetrix Inc:Raises adjusted EBITDA guidance from a range of 16-18% to 17-19% for FY 2015.Reiterate FY 2015 revenues guidance of mid-single-digit growth on a constant-currency basis.Reported revenue of $349.02 mln and EBITDA of $42.67 mln in FY 2014.FY 2015 revenues of $361.43 and EBITDA of $56.35...

4:00pm EDT

Foundation Medicine Inc lowers FY 2015 revenue guidance

Foundation Medicine Inc:Expects FY 2015 revenue will be in the range of $85 to $95 million.FY 2015 revenue of $106 mln - Thomson Reuters I/B/E/S.

4:00pm EDT

Cytokinetics Inc Updates FY 2015 cash revenue Guidance

Cytokinetics Inc:Expects FY 2015 cash revenue to be in the range of $44 to $47 million.

4:00pm EDT

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.